血红蛋白糖化指数与2型糖尿病低血糖风险之间的关系,目标范围内的时间范围
Bei-Si Lin1, Zhi-Gu Liu1, Dan-Rui Chen1
1Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou 510630, Guangdong Province, China.
World journal of diabetes
|November 4, 2024
概括
血红蛋白糖化指数 (HGI) 预测2型糖尿病患者的低血糖,即使血糖控制良好. 较高的HGI表明低血糖和血糖外流的风险增加.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 糖尿病管理 糖尿病管理
背景情况:
- 低血糖是2型糖尿病 (T2DM) 的风险,即使时间范围 (TIR) > 70%.
- 血红蛋白糖化指数 (HGI) 是低血糖的关键预测指标.
- HGI为个性化T2DM治疗提供了洞察力,特别是对于看似控制良好葡萄糖的患者.
研究的目的:
- 检查T2DM患者中HGI和低血糖之间的关联.
- 为了评估HGI在T2DM中低血糖的预测值,TIR>70%.
主要方法:
- 在129名T2DM患者中使用了7天的连续葡萄糖监测 (CGM).
- 计算HGI是HbA1c减去葡萄糖管理指标.
- 患者被分为低HGI (<0.5) 和高HGI (≥0.5) 的两组;进行了后勤回归和ROC分析.
主要成果:
- 高HGI组显示TIR较低,在范围以下的时间较长,HbA1c较高,表明血糖偏差和低血糖风险增加.
- 平均血糖,血糖标准偏差和HGI是低血糖的独立危险因素.
- 高血糖基因显示出最强的低血糖预测能力 (最佳切断值为0.5%).
结论:
- 升高的HGI与T2DM患者TIR>70%的更高的血糖变异性和更高的低血糖发生率相关.
- 在这种患者群中,HGI作为可靠的生物标志物用于预测低血糖症.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152
Diabetes: Symptoms, Diagnosis, and Complications
508
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
508
Oral Hypoglycemic Agents: Glinides
141
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
141
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
175
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
175


